[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1984

The Effects of Ceruletide in Schizophrenia

Author Affiliations

From the National Institute of Mental Health, Clinical Neuroscience Branch, Bethesda, Md. Dr Ninan is now with the Department of Psychiatry, Emory University Clinic, Atlanta. Dr Boronow is now with the Sheppard Pratt Hospital, Baltimore.

Arch Gen Psychiatry. 1984;41(6):617-619. doi:10.1001/archpsyc.1984.01790170091010
Abstract

• Eight neuroleptic-resistant schizophrenic patients were treated with ceruletide diethylamine, a cholecystokininlike peptide, in a placebo-controlled, double-blind, cross-over study. Ceruletide or placebo was administered intramuscularly twice a day for four consecutive days while patients received a constant dose of fluphenazine hydrochloride. Cholecystokinin octapeptide was also administered to four different schizophrenic patients in a double-blind, cross-over study. Cholecystokinin or placebo was administered as a slow intravenous infusion daily for four days. There were no changes in either the positive or negative symptoms of schizophrenia between the periods of placebo, ceruletide, or cholecystokinin administration. Furthermore, there was no tendency for the patients' conditions to either improve or worsen during the course of ceruletide or cholecystokinin treatment. In contrast to previous reports from uncontrolled studies, cholecystokininlike peptides appear to be devoid of antipsychotic properties when administered parenterally.

×